Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Rating Lowered by Citizens Jmp

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) was downgraded by equities researchers at Citizens Jmp from an "outperform" rating to a "market perform" rating in a report released on Monday, Marketbeat Ratings reports.

Several other brokerages also recently commented on IRWD. Craig Hallum cut their price objective on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a "buy" rating on the stock in a research report on Wednesday, January 22nd. JMP Securities lowered their price target on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a "market outperform" rating on the stock in a report on Thursday, January 30th. Finally, StockNews.com upgraded Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, March 29th. Eight research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $4.78.

Ironwood Pharmaceuticals Stock Performance

Shares of NASDAQ IRWD traded down $0.03 during midday trading on Monday, hitting $0.73. 3,326,562 shares of the company traded hands, compared to its average volume of 2,563,472. Ironwood Pharmaceuticals has a 12-month low of $0.59 and a 12-month high of $8.45. The firm has a market cap of $117.31 million, a P/E ratio of -24.17 and a beta of 0.30. The stock has a 50-day moving average price of $1.44 and a 200 day moving average price of $3.02.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.08). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The business had revenue of $90.55 million for the quarter, compared to the consensus estimate of $93.85 million. As a group, equities analysts expect that Ironwood Pharmaceuticals will post 0.1 earnings per share for the current year.

Insider Buying and Selling

In other Ironwood Pharmaceuticals news, CMO Michael Shetzline sold 41,269 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $1.76, for a total transaction of $72,633.44. Following the completion of the transaction, the chief marketing officer now owns 554,007 shares in the company, valued at $975,052.32. This trade represents a 6.93 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Thomas A. Mccourt sold 139,064 shares of the business's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $244,752.64. Following the sale, the chief executive officer now directly owns 1,160,634 shares in the company, valued at $2,042,715.84. The trade was a 10.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 192,381 shares of company stock worth $338,591. 12.90% of the stock is owned by corporate insiders.

Institutional Trading of Ironwood Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. boosted its holdings in Ironwood Pharmaceuticals by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 33,932 shares of the biotechnology company's stock worth $150,000 after buying an additional 3,209 shares in the last quarter. Quantinno Capital Management LP grew its stake in Ironwood Pharmaceuticals by 40.0% in the 3rd quarter. Quantinno Capital Management LP now owns 19,191 shares of the biotechnology company's stock valued at $79,000 after acquiring an additional 5,482 shares during the period. Swiss National Bank raised its position in Ironwood Pharmaceuticals by 2.2% during the fourth quarter. Swiss National Bank now owns 282,700 shares of the biotechnology company's stock worth $1,252,000 after acquiring an additional 6,000 shares during the period. Teacher Retirement System of Texas lifted its holdings in Ironwood Pharmaceuticals by 19.6% during the fourth quarter. Teacher Retirement System of Texas now owns 42,893 shares of the biotechnology company's stock valued at $190,000 after purchasing an additional 7,020 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Ironwood Pharmaceuticals in the fourth quarter valued at about $36,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.